Long-Term Follow-Up of Patients with Scleritis After Rituximab Treatment Including B Cell Monitoring-Reference-Cited by-同舟云学术

Long-Term Follow-Up of Patients with Scleritis After Rituximab Treatment Including B Cell Monitoring

Published:2023-07-12 Issue: Volume: Page:1-6
ISSN:0927-3948
Container-title:Ocular Immunology and Inflammation
language:en
Short-container-title:Ocular Immunology and Inflammation

Author:

van Bilsen Kiki¹²,Vergouwen Daphne P. C.²³,van Velthoven Mirjam E. J.⁴^ORCID,Missotten Tom O. A. R.⁴,Rombach Saskia M.¹²,van Zelm Menno C.²⁵,Berkowska Magdalena A.¹⁶,van Hagen P. Martin¹²,Kuijpers Robert W. A. M.³⁷⁸,van Laar Jan A. M.¹²

Affiliation:

1. Department of Internal Medicine, Section Clinical Immunology Erasmus MC, University Medical Center, Rotterdam, The Netherlands

2. Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands

3. Department of Ophthalmology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands

4. Centrum Medical Retinal and Uveitis, The Rotterdam Eye Hospital, Rotterdam, The Netherlands

5. Department of Immunology and Pathology, Central Clinical School, Monash University and Alfred Hospital, Melbourne, Australia

6. Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands

7. Department of Ophthalmology, Albert Schweitzer Hospital, Dordrecht, The Netherlands

8. Department of Ophthalmology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium

Funder

no funding associated with the work featured in this article

Publisher

Informa UK Limited

Subject

Ophthalmology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/09273948.2023.2229900

Reference30 articles.

1. EPISCLERITIS AND SCLERITIS. I

2. Scleritis: Immunopathogenesis and molecular basis for therapy

3. Visual Outcome, Treatment Results, and Prognostic Factors in Patients with Scleritis